Pemetrexed Market Report 2025 (Global Edition)

Global Pemetrexed Market Report 2025 Market Size Split by Strength (100mg, 200mg), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), by End User (Hospital Pharmacies...

Pemetrexed Market Report Description

We have various report editions of Pemetrexed Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Impact of Tariff Trumph on Pharmaceuticals Industry

The reintroduction of tariffs under President Trump’s “Liberation Day Tariffs” in April 2025 has created significant disruption in global pharmaceutical trade. These tariffs, ranging from 10% to 46%, specifically target pharmaceutical products, APIs (active pharmaceutical ingredients), medical packaging, and machinery from key manufacturers in China and India. This has led to increased production costs, supply chain delays, and regulatory challenges for U.S.-based pharmaceutical companies.

The tariffs have particularly impacted generic drug manufacturers, who rely heavily on APIs from China and India. Biopharmaceuticals and vaccines are also feeling the pressure, with tariffs on critical materials like bioproduction media and cold-chain packaging raising costs by up to 25%. Similarly, contract manufacturing organizations (CMOs) are grappling with the need to identify new suppliers and adjust production plans to mitigate rising costs.

Foreign governments, including the European Union, have retaliated with tariffs on U.S. pharmaceutical exports, further complicating global trade. Clinical trials are also impacted, as tariffs on drugs and diagnostic kits delay trial timelines.

Market research is increasingly crucial for navigating these challenges. By providing real-time data on API pricing, supplier reliability, and tariff impact, pharmaceutical firms can make informed decisions on sourcing, compliance, and investment strategies. This data-driven approach helps mitigate risks, optimize supply chains, and identify alternative manufacturing hubs to offset tariff-related disruptions.

Overall, market research is essential for pharmaceutical companies to adapt to the new tariff landscape, enabling them to maintain competitive advantage and navigate global trade dynamics effectively.

Pemetrexed Market Insights Video

Competitive Landscape of the Pemetrexed Market

The Pemetrexed Market features key players such as Eli Lilly and Company, Pfizer Inc., and Fresenius Kabi, among others. These companies compete in offering innovative formulations, expanding indications, and strategic partnerships to maintain their market share and meet the growing demand for advanced cancer treatments globally.

January 2023: Sun Pharma, an Indian pharmaceutical company, purchases Concert, a U.S.-based company, for $576 million. (Source: https://www.reuters.com/markets/deals/indias-sun-pharma-acquire-us-based-concert-576-mln-2023-01-19/ ) May 2022: Hengrui Pharma reports that in a global Phase 3 trial for advanced hepatocellular carcinoma, the combination of frontline Camrelizumab with Rivoceranib notably enhanced progression-free survival and overall survival. (Source: https://www.hengrui.com/en/media/detail-244.html )

Top Companies Market Share in Pemetrexed Industry: (In no particular order of Rank)

• Eli Lilly and Company (USA)
• Pfizer Inc. (USA)
• Fresenius Kabi (Germany)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Accord Healthcare Limited (U.K.)
• Dr. Reddy's Laboratories Ltd. (India)
• Mylan N.V. (USA)
• Sun Pharmaceutical Industries Ltd. (India)
• Sandoz International GmbH (Germany)
• Jiangsu Hengrui Medicine Co.
• Ltd. (China)
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Pemetrexed Market

Which Region Dominates the Pemetrexed Market in 2024?

According to Cognitive Market Research, North America emerges as the dominant region in the Pemetrexed Market. This dominance is attributed to several factors, including the high prevalence of lung cancer and mesothelioma in the region, robust healthcare infrastructure, strong focus on research and development, and early adoption of advanced cancer treatments. Furthermore, key players like Eli Lilly and Company, Pfizer Inc., and others have a significant presence and market share in North America, contributing to its dominance in the Pemetrexed Market.

Which Region is Expanding at the Fastest CAGR?

Asia-Pacific stands out as the fastest-growing region in the Pemetrexed Market. This growth is fueled by several factors, including rapid industrialization and urbanization in countries like China and India, increasing healthcare expenditure, rising awareness about cancer treatment options, and growing investments in healthcare infrastructure. Moreover, the large patient population, especially in densely populated countries in Asia-Pacific, creates a substantial demand for advanced cancer therapies like Pemetrexed, driving the region's rapid growth in the Pemetrexed Market.

 

The current report Scope analyzes Pemetrexed Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Switzerland, Luxembourg, Rest of Europe)
• Asia Pacific (China, Japan, South Korea, India, Australia, Singapore, Taiwan, South East Asia, Rest of APAC)
• Latin America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East (Saudi Arabia, Turkey, UAE, Egypt, Qatar, Rest of Middle East)
• Africa (Nigeria, South Africa, Rest of Africa)

The above graph is for illustrative purposes only.

North America Pemetrexed Market Analysis

According to Cognitive Market Research, the global Pemetrexed Market size was estimated at USD 2541.2 Million, out of which North America held the major market of more than 40% of the global revenue with a market size of USD 1016.48 million in 2024 and will grow at a compound annual growth rate (CAGR) of 0.7 % from 2024 to 2031.

• According to Cognitive Market Research, the U.S. had a major share in the Pemetrexed Market with a market size of USD 802.00 million in 2024 and is projected to grow at a CAGR of 0.5 % during the forecast period. The demand is amplified by the nation's Advanced oncology treatment facilities and high cancer prevalence.
• The Canada Pemetrexed Market had a market share of USD 121.98 million in 2024 and is projected to grow at a CAGR of 1.5 % during the forecast period. Canada's Strong Healthcare System and Increasing Cancer Research Funding to Increased Usage of Pemetrexed.
• The Mexico Pemetrexed Market is projected to witness growth at a CAGR of 1.2 % during the forecast period, with a market size of USD 92.50 million in 2024.

Europe Pemetrexed Market Analysis

According to Cognitive Market Research, the global Pemetrexed Market size was estimated at USD 2541.2 Million, out of which Europe held the market more than 30% of the global revenue with a market size of USD 762.36 million in 2024 and will grow at a compound annual growth rate (CAGR) of 1.0 % from 2024 to 2031.

• The United Kingdom Pemetrexed Market had a market share of USD 128.08 million in 2024 and is projected to grow at a CAGR of 1.8 % during the forecast period. In the U.K., Pemetrexed sales witness an upswing due to the Comprehensive cancer treatment programs and significant healthcare expenditure.
• The France Pemetrexed Market is projected to witness growth at a CAGR of 0.2 % during the forecast period, with a market size of USD 70.14 million in 2024.
• According to Cognitive Market Research, the Germany Pemetrexed Market size was valued at USD 150.95 million in 2024 and is projected to grow at a CAGR of 1.2 % during the forecast period. In Germany, Pemetrexed sales surged due to the High healthcare standards and extensive cancer treatment infrastructure.
• The Italy Pemetrexed Market is projected to witness growth at a CAGR of 0.4 % during the forecast period, with a market size of USD 65.56 million in 2024.
• The Russia Pemetrexed Market is projected to witness growth at a CAGR of 0.0 % during the forecast period, with a market size of USD 118.17 million in 2024.
• The Spain Pemetrexed Market is projected to witness growth at a CAGR of 0.1 % during the forecast period with a market size of USD 62.51 million in 2024
• The Luxembourg Pemetrexed Market is projected to witness growth at a CAGR of 1.1 % during the forecast period, with a market size of USD 23.63 million in 2024.
• The Portugal Pemetrexed Market is projected to witness growth at a CAGR of 0.8 % during the forecast period, with a market size of USD 16.01 million in 2024.
• The Greece Pemetrexed Market is projected to witness growth at a CAGR of 1.3 % during the forecast period, with a market size of USD 9.15 million in 2024.
• Rest of Europe's Pemetrexed Market is projected to witness growth at a CAGR of -0.3 % during the forecast period, with a market size of USD 118.17 million in 2024.

Asia Pacific Pemetrexed Market Analysis

According to Cognitive Market Research, the global Pemetrexed Market size was estimated at USD 2541.2 Million, out of which Asia Pacific held the market of around 23% of the global revenue with a market size of USD 584.48 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.5 % from 2024 to 2031.

• According to Cognitive Market Research, the China Pemetrexed Market size was valued at USD 263.01 million in 2024 and is projected to grow at a CAGR of 4.0 % during the forecast period. Pemetrexed sales surge in China due to the Rapidly growing healthcare infrastructure and increasing cancer incidence.
• The Japan Pemetrexed Market is projected to witness growth at a CAGR of 3.0 % during the forecast period, with a market size of USD 80.66 million in 2024.
• The India Pemetrexed Market had a market share of USD 70.14 million in 2024 and is projected to grow at a CAGR of 6.3 % during the forecast period. India's Rising cancer awareness and improving access to cancer treatments augment the demand.
• The South Korea Pemetrexed Market is projected to witness growth at a CAGR of 3.6 % during the forecast period, with a market size of USD 58.45 million in 2024.
• The Australia Pemetrexed Market is projected to witness growth at a CAGR of 4.2 % during the forecast period, with a market size of USD 30.39 million in 2024.
• The South East Asia Pemetrexed Market is projected to witness growth at a CAGR of 5.5 % during the forecast period, with a market size of USD 40.33 million in 2024.
• The Rest of Asia Pacific Pemetrexed Market is projected to witness growth at a CAGR of 4.3 % during the forecast period, with a market size of USD 41.50 million in 2024.

South America Pemetrexed Market Analysis

According to Cognitive Market Research, the global Pemetrexed Market size was estimated at USD 2541.2 Million, out of which the Latin America market of more than 5% of the global revenue with a market size of USD 127.06 million in 2024. It will grow at a compound annual growth rate (CAGR) of 1.9 % from 2024 to 2031.

• According to Cognitive Market Research, the Brazil Pemetrexed Market size was valued at USD 54.38 million in 2024 and is projected to grow at a CAGR of 2.5 % during the forecast period. Pemetrexed sales flourished in Brazil due to the Expanding healthcare services and increasing focus on cancer treatment.
• Argentina Pemetrexed Market had a market share of USD 21.35 million in 2024 and is projected to grow at a CAGR of 2.8 % during the forecast period. Argentina's Growing healthcare sector and rising prevalence of cancer augment the demand.
• Colombia Pemetrexed Market is projected to witness growth at a CAGR of 1.7 % during the forecast period, with a market size of USD 11.31 million in 2024.
• Peru Pemetrexed Market is projected to witness growth at a CAGR of 2.1 % during the forecast period, with a market size of USD 10.42 million in 2024.
• Chile Pemetrexed Market is projected to witness growth at a CAGR of 2.2 % during the forecast period, with a market size of USD 9.15 million in 2024.
• The Rest of Latin America Pemetrexed Market is projected to witness growth at a CAGR of 1.0 % during the forecast period, with a market size of USD 20.46 million in 2024.

Middle East Pemetrexed Market Analysis

According to Cognitive Market Research, the global Pemetrexed Market size was estimated at USD 2541.2 Million, out of which the Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD 50.82 million in 2024 and will grow at a compound annual growth rate (CAGR) of 2.2 % from 2024 to 2031.

• The GCC Countries Pemetrexed Market is projected to witness growth at a CAGR of 3.0 % during the forecast period, with a market size of USD 21.75 million in 2024. Pemetrexed sales flourished due to the Improved healthcare infrastructure and significant investments in oncology.
• The Egypt Pemetrexed Market is projected to witness growth at a CAGR of 2.5 % during the forecast period, with a market size of USD 5.34 million in 2024.
• The South Africa Pemetrexed Market is projected to witness growth at a CAGR of 3.2 % during the forecast period, with a market size of USD 8.03 million in 2024. Pemetrexed sales flourished in South Africa due to the enhancement of cancer care facilities and increasing awareness.
• The Turkey Pemetrexed Market is projected to witness growth at a CAGR of 1.7 % during the forecast period, with a market size of USD 4.37 million in 2024.
• The Nigeria Pemetrexed Market is projected to witness growth at a CAGR of 1.3 % during the forecast period, with a market size of USD 5.34 million in 2024.
• The Rest of the MEA Pemetrexed Market is projected to witness growth at a CAGR of 1.2 % during the forecast period, with a market size of USD 6.00 million in 2024.

Pemetrexed Market Analysis

Pemetrexed Market Strength Segment Analysis

According to Cognitive Market Research, The largest strength in the Pemetrexed Market is typically the 500mg dosage, which is commonly used in oncology treatments, especially for lung cancer and mesothelioma. This dosage strength allows for the effective administration of Pemetrexed while minimizing the number of doses required, enhancing patient convenience and treatment adherence. Pharmaceutical companies often prioritize the production and marketing of the 500mg strength due to its widespread usage and demand in cancer therapy.

The fastest-growing strength in the Pemetrexed Market is the 100mg dosage. This strength is gaining popularity due to several factors, including its suitability for certain patient populations, such as those requiring lower doses or experiencing sensitivity to higher concentrations. Additionally, advancements in personalized medicine and targeted therapies have led to increased utilization of lower dosage strengths like 100mg to optimize treatment outcomes while reducing potential side effects. As a result, the demand for the 100mg strength is experiencing rapid growth in the Pemetrexed Market.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Pemetrexed Industry. Request a Free Sample PDF!

Pemetrexed Market Distribution Channel Segment Analysis

According to Cognitive Market Research, the largest distribution channel in the Pemetrexed Market is typically hospital pharmacies. Hospitals serve as major healthcare facilities where a significant volume of Pemetrexed and other cancer treatments are dispensed and administered. Oncologists and healthcare professionals in hospitals frequently prescribe Pemetrexed for cancer patients, leading to a substantial demand for this medication through hospital pharmacies. Moreover, hospitals often have established relationships with pharmaceutical suppliers, ensuring a steady supply of Pemetrexed to meet patient needs.

The fastest-growing distribution channel in the Pemetrexed Market is online pharmacies. The rise of e-commerce and digital healthcare platforms has revolutionized how medications are accessed and purchased. Online pharmacies offer convenience, accessibility, and often competitive pricing for medications like Pemetrexed. Patients can order their prescriptions online and have them delivered to their doorstep, eliminating the need for physical visits to traditional brick-and-mortar pharmacies. This convenience factor has fueled the rapid growth of online pharmacies as a preferred channel for purchasing Pemetrexed and other pharmaceutical products.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Pemetrexed End User Segment Analysis

According to Cognitive Market Research, The largest end users in the Pemetrexed Market are pharmaceutical companies. These companies are responsible for manufacturing, marketing, and distributing Pemetrexed to various healthca

• Hospital Pharmacies
• Pharmaceutical Companies

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Author's Conclusion